Bayer off to a Successful Start in 2016
- Group sales increase by 3.2% (Fx & portfolio adj.) to €11.9 billion, EBITDA before special items by 15.7% to €3.4 billion
- Substantial sales growth at Pharmaceuticals
- Earnings expand in all segments
- Forecast for 2016 confirmed
Bayer got off to a successful start in the new fiscal year. In the first quarter of 2016, the Bayer Group improved sales by 3.2% (Fx & portfolio adj.) to €11.9 billion and EBITDA before special items by 15.7% to €3.4 billion. All segments improved their operating performance. At Pharmaceuticals, we again benefited from the very good development of our recently launched products. Business with our Consumer Health products developed positively. Crop Science outperformed the prior-year quarter despite a weak market environment. Animal Health posted substantial gains. Our Life Science businesses therefore showed encouraging development. Sales at Covestro declined as anticipated, while EBITDA before special items rose significantly. We are confirming our forecast.